TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.
Highlights:
Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.
Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.
This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.
Read more here
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.